By Fineline Cube Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new licensing agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. (Molteni Farmaceutici), a prominent Italian pharmaceutical firm. The deal grants Molteni exclusive rights to develop and commercialize efbemalenograstim alfa (F-627) in Italy and Poland, marking Yifan’s entry into its 17th European country/region.
Deal & Asset Profile
| Item | Detail |
|---|---|
| Licenser | Yifan Pharmaceutical Co., Ltd. (SHE: 002019) |
| Licensee | Molteni Farmaceutici (Italy) |
| Asset | Efbemalenograstim alfa (F-627) |
| Indication | Prevention and treatment of chemotherapy-induced neutropenia (CIN) in cancer patients |
| Territory | Italy and Poland |
| Technology Platform | Di-Kine dual-molecule technology |
| Molecule Type | Recombinant human G-CSF (rhG-CSF) dimer, Fc-fusion protein expressed in CHO cells |
| Key Attributes | Long-acting, potent biological activity |
Clinical & Commercial Rationale
Efbemalenograstim alfa is a next-generation “white blood cell booster” designed to mitigate a critical side effect of chemotherapy. By enabling the rapid proliferation and recovery of neutrophils, the drug significantly reduces the risk of life-threatening infections in immunocompromised cancer patients, allowing them to stay on their prescribed treatment regimens.
This partnership leverages Molteni Farmaceutici’s established commercial infrastructure and market expertise in Southern and Central Europe to accelerate patient access to this innovative therapy. For Yifan, the deal is a key component of its capital-efficient global expansion strategy, building on a growing network of regional partners across the continent.
Strategic Context
The European market for long-acting G-CSF agents is mature but remains essential for comprehensive oncology care. Yifan’s ability to secure its 17th European partnership underscores the strong clinical profile and commercial viability of efbemalenograstim alfa. The use of its proprietary Di-Kine platform to create a potent, long-acting dimer positions the asset favorably against existing standard-of-care treatments.
Forward-Looking Statements
This brief contains forward-looking statements regarding the regulatory and commercial success of efbemalenograstim alfa in Italy and Poland. Actual results will be subject to local regulatory approvals, pricing and reimbursement negotiations, and market competition.-Fineline Info & Tech